Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00049088 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: docetaxel
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)